William Clark
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
William Clark has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Colin Nixon
Cancer Research UK Scotland Institute, Glasgow, United Kingdom
19 shared publications - Dale M. Watt
Cancer Research UK Scotland Institute, Glasgow, G61 1BD, United Kingdom
19 shared publications - Owen James Sansom
School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom
19 shared publications - Andrew D. Campbell
Cancer Research UK Scotland Institute, Glasgow, United Kingdom
18 shared publications - Arafath Kaja Najumudeen
Cancer Research UK Scotland Institute, Glasgow, UK
18 shared publications - Catriona A. Ford
Cancer Research UK Scotland Institute, Glasgow, UK
18 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Loss of wild-type KRAS sensitizes KPC KrasG12D/fl tumours to MEK1/2 inhibition.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Loss of wild-type KRAS sensitizes KPC KrasG12D/fl tumours to MEK1/2 inhibition.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Acceleration of pancreatic tumour initiation after loss of wild-type Kras in KPC KrasG12D/fl mice.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Acceleration of pancreatic tumour initiation after loss of wild-type Kras in KPC KrasG12D/fl mice.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Release from AZD6244 treatment results in rapid acinar to ductal metaplasia in KC KrasG12D/fl.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Release from AZD6244 treatment results in rapid acinar to ductal metaplasia in KC KrasG12D/fl.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Increased fibrosis in wild-type Kras deficient PanINs.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Increased fibrosis in wild-type Kras deficient PanINs.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
MEK1/2 inhibition in KPC KrasG12D/fl mice with established tumours reverses enrichment of immune response related gene programmes.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
MEK1/2 inhibition in KPC KrasG12D/fl mice with established tumours reverses enrichment of immune response related gene programmes.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Loss of wild-type KRAS does not alter PI3K-AKT signalling.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Loss of wild-type KRAS does not alter PI3K-AKT signalling.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Loss of WT Kras increases PanIN formation in the presence of oncogenic Kras. A, Kaplan–Meier survival curve for human patients with PDAC with KRAS alleles balanced and KRAS alleles imbalanced. KRAS balanced, n = 47; KRAS imbalanced, n = 32. *, P = 0.029, log-rank (Mantel–Cox) test. B, Proportion of human patients with pancreatic cancer with KRAS alleles balanced (59.5%) and KRAS alleles imbalanced (40.5%), from A. C, Schematic representing generation of KC KrasG12D/fl mice. D, Representative hematoxylin and eosin (H&E) images of pancreata from KC KrasG12D/+ and KC KrasG12D/fl mice at 42 days of age, representative of six mice per group. Scale bar, 200 μm. E, Quantification and grading of PanINs from KC KrasG12D/+ and KC KrasG12D/fl mice at 42 days of age from one whole hematoxylin and eosin section per mouse (n = 6 per group), represented by D. Boxes depict the IQR, the central line indicates the median, and whiskers indicate minimum/maximum values. **, P < 0.01; one-way Mann–Whitney U test. F, Quantification of the area of ADM per mm2 pancreas over one whole hematoxylin and eosin section from KC KrasG12D/+ and KC KrasG12D/fl mice at 42 days of age (n = 6 per group). Boxes depict the IQR, the central line indicates the median, and whiskers indicate minimum/maximum values. **, P < 0.0011; one-way Mann–Whitney U test. G, Left, representative IHC images of pERK1/2 of pancreata from KC KrasG12D/+ and KC KrasG12D/fl mice at 42 days of age. Representative of six mice per group. Scale bar, 200 μm. Right, bar graphs showing quantification of pERK1/2-positive cells of the pancreatic epithelium of KC KrasG12D/+ and KC KrasG12D/fl mice sampled at day 42 (KC KrasG12D/+, n = 6; KC KrasG12D/fl, n = 6). Data are the mean ± SEM. *, P = 0.0325; one-way Mann–Whitney U test. H, Left, representative images of ISH of Dusp5 and Dusp6 of pancreata from KC KrasG12D/+ and KC KrasG12D/fl mice at 42 days of age. Representative of six mice per group. Scale bar, 200 μm. Right, quantification of Dusp5 and Dusp6 ISH staining of pancreatic lesions (PanINs) of pancreata from KC KrasG12D/+ and KC KrasG12D/fl mice at 42 days of age (KC KrasG12D/+, n = 6; KC KrasG12D/fl, n = 6). Data are the mean ± SEM. **, P = 0.0011 (Dusp5); **, P = 0.0022 (Dusp6); one-way Mann–Whitney U test. Cre, Cre recombinase; loxP, Cre-loxP recombination site.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Loss of WT Kras increases PanIN formation in the presence of oncogenic Kras. A, Kaplan–Meier survival curve for human patients with PDAC with KRAS alleles balanced and KRAS alleles imbalanced. KRAS balanced, n = 47; KRAS imbalanced, n = 32. *, P = 0.029, log-rank (Mantel–Cox) test. B, Proportion of human patients with pancreatic cancer with KRAS alleles balanced (59.5%) and KRAS alleles imbalanced (40.5%), from A. C, Schematic representing generation of KC KrasG12D/fl mice. D, Representative hematoxylin and eosin (H&E) images of pancreata from KC KrasG12D/+ and KC KrasG12D/fl mice at 42 days of age, representative of six mice per group. Scale bar, 200 μm. E, Quantification and grading of PanINs from KC KrasG12D/+ and KC KrasG12D/fl mice at 42 days of age from one whole hematoxylin and eosin section per mouse (n = 6 per group), represented by D. Boxes depict the IQR, the central line indicates the median, and whiskers indicate minimum/maximum values. **, P < 0.01; one-way Mann–Whitney U test. F, Quantification of the area of ADM per mm2 pancreas over one whole hematoxylin and eosin section from KC KrasG12D/+ and KC KrasG12D/fl mice at 42 days of age (n = 6 per group). Boxes depict the IQR, the central line indicates the median, and whiskers indicate minimum/maximum values. **, P < 0.0011; one-way Mann–Whitney U test. G, Left, representative IHC images of pERK1/2 of pancreata from KC KrasG12D/+ and KC KrasG12D/fl mice at 42 days of age. Representative of six mice per group. Scale bar, 200 μm. Right, bar graphs showing quantification of pERK1/2-positive cells of the pancreatic epithelium of KC KrasG12D/+ and KC KrasG12D/fl mice sampled at day 42 (KC KrasG12D/+, n = 6; KC KrasG12D/fl, n = 6). Data are the mean ± SEM. *, P = 0.0325; one-way Mann–Whitney U test. H, Left, representative images of ISH of Dusp5 and Dusp6 of pancreata from KC KrasG12D/+ and KC KrasG12D/fl mice at 42 days of age. Representative of six mice per group. Scale bar, 200 μm. Right, quantification of Dusp5 and Dusp6 ISH staining of pancreatic lesions (PanINs) of pancreata from KC KrasG12D/+ and KC KrasG12D/fl mice at 42 days of age (KC KrasG12D/+, n = 6; KC KrasG12D/fl, n = 6). Data are the mean ± SEM. **, P = 0.0011 (Dusp5); **, P = 0.0022 (Dusp6); one-way Mann–Whitney U test. Cre, Cre recombinase; loxP, Cre-loxP recombination site.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Loss of WT KRAS induces increased MAPK signaling in KPC KrasG12D/fl. A, Experimental schematic representing mice imaged once weekly by ultrasound from 6 weeks of age to clinical endpoint to follow tumor growth over time. B, Tumor volume relative to that of tumor at initial detection from KPC KrasG12D/+ and KPC KrasG12D/fl mice aged to clinical endpoint and measured once weekly by ultrasound imaging from 6 weeks of age. KPC KrasG12D/fl, n = 8; KPC KrasG12D/+, n = 10. FC, fold change. C, Kaplan–Meier survival curves for KPC KrasG12D/+ and KPC KrasG12D/fl mice aged to clinical endpoint. KPC KrasG12D/fl, n = 29; KPC KrasG12D/+, n = 23. *, P = 0.0396 log-rank (Mantel–Cox) test. Mice were censored when reaching clinical endpoint not associated with PDAC burden, such as primary tumors, which arose from other tissue, mostly mucocutaneous papillomas or lymphomas (typically thymic) but also gastric and lung tumors. MS, median survival. D, Incidence of metastasis (%) in KPC KrasG12D/+ and KPC KrasG12D/fl mice. KPC KrasG12D/fl, n = 27; KPC KrasG12D/+, n = 20. mets, metastasis. E, Migration speed of established cell lines derived from pancreatic cancers arising in KPC KrasG12D/+ and KPC KrasG12D/fl mice. F, Relative probe intensity in ddPCR from tumors arising in KPC KrasG12D/+ (n = 16) and KPC KrasG12D/fl (n = 9) mice at clinical endpoint, comparing KrasG12D to KrasWT and KrasG12D to Gapdh probe sets. Tumors from which cell lines analyzed in I were generated are highlighted in this analysis. G, Representative IHC images of CD3, CD4, and CD8a from PDAC arising in KPC KrasG12D/+ and KPC KrasG12D/fl mice taken at clinical endpoint. Representative of five mice per group. Scale bar, 200 μm. H, Bar graphs showing quantification of proportion of CD3-, CD4-, and CD8a-positive cells in PDAC tissue from KPC KrasG12D/+ and KPC KrasG12D/fl mice sampled at clinical endpoint (KPC KrasG12D/+, n = 5; KPC KrasG12D/fl, n = 5). Data are the mean ± SEM, represented in G. I, Immunoblotting of pMEK1/2, MEK1/2, pERK1/2, ERK1/2, and KrasG12D of KPC KrasG12D/+ and KPC KrasG12D/fl PDAC tissue lysates generated from mice at clinical endpoint. β-Actin was used as a loading control. Each lane represents PDAC tissue from an individual mouse of the indicated genotype. Bar graph shows quantification of pMEK1/2 levels, normalized to MEK1/2; pERK1/2 levels, normalized to ERK1/2; and KRAS-G12D levels, normalized to β-actin. Data represent the mean ± SEM. *, P = 0.0143; one-way Mann–Whitney U test. J, qRT-PCR analysis of Etv4, Etv5, Dusp4, Dusp6, Spry1, and Spry2 in KPC KrasG12D/+ and KPC KrasG12D/fl PDAC tissue. Transcript levels were normalized to Gapdh (KPC KrasG12D/+, n = 5; KPC KrasG12D/fl, n = 6). Data represent the mean ± SEM. P = 0.2 (Etv4); **, P = 0.0087 (Etv5); P = 0.4 (Dusp4); **, P = 0.0087 (Dusp6); *, P = 0.0152 (Spry1); and *, P = 0.0411 (Spry2); ns, nonsignificant; one-way Mann–Whitney U test. Rel., relative.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Loss of WT KRAS induces increased MAPK signaling in KPC KrasG12D/fl. A, Experimental schematic representing mice imaged once weekly by ultrasound from 6 weeks of age to clinical endpoint to follow tumor growth over time. B, Tumor volume relative to that of tumor at initial detection from KPC KrasG12D/+ and KPC KrasG12D/fl mice aged to clinical endpoint and measured once weekly by ultrasound imaging from 6 weeks of age. KPC KrasG12D/fl, n = 8; KPC KrasG12D/+, n = 10. FC, fold change. C, Kaplan–Meier survival curves for KPC KrasG12D/+ and KPC KrasG12D/fl mice aged to clinical endpoint. KPC KrasG12D/fl, n = 29; KPC KrasG12D/+, n = 23. *, P = 0.0396 log-rank (Mantel–Cox) test. Mice were censored when reaching clinical endpoint not associated with PDAC burden, such as primary tumors, which arose from other tissue, mostly mucocutaneous papillomas or lymphomas (typically thymic) but also gastric and lung tumors. MS, median survival. D, Incidence of metastasis (%) in KPC KrasG12D/+ and KPC KrasG12D/fl mice. KPC KrasG12D/fl, n = 27; KPC KrasG12D/+, n = 20. mets, metastasis. E, Migration speed of established cell lines derived from pancreatic cancers arising in KPC KrasG12D/+ and KPC KrasG12D/fl mice. F, Relative probe intensity in ddPCR from tumors arising in KPC KrasG12D/+ (n = 16) and KPC KrasG12D/fl (n = 9) mice at clinical endpoint, comparing KrasG12D to KrasWT and KrasG12D to Gapdh probe sets. Tumors from which cell lines analyzed in I were generated are highlighted in this analysis. G, Representative IHC images of CD3, CD4, and CD8a from PDAC arising in KPC KrasG12D/+ and KPC KrasG12D/fl mice taken at clinical endpoint. Representative of five mice per group. Scale bar, 200 μm. H, Bar graphs showing quantification of proportion of CD3-, CD4-, and CD8a-positive cells in PDAC tissue from KPC KrasG12D/+ and KPC KrasG12D/fl mice sampled at clinical endpoint (KPC KrasG12D/+, n = 5; KPC KrasG12D/fl, n = 5). Data are the mean ± SEM, represented in G. I, Immunoblotting of pMEK1/2, MEK1/2, pERK1/2, ERK1/2, and KrasG12D of KPC KrasG12D/+ and KPC KrasG12D/fl PDAC tissue lysates generated from mice at clinical endpoint. β-Actin was used as a loading control. Each lane represents PDAC tissue from an individual mouse of the indicated genotype. Bar graph shows quantification of pMEK1/2 levels, normalized to MEK1/2; pERK1/2 levels, normalized to ERK1/2; and KRAS-G12D levels, normalized to β-actin. Data represent the mean ± SEM. *, P = 0.0143; one-way Mann–Whitney U test. J, qRT-PCR analysis of Etv4, Etv5, Dusp4, Dusp6, Spry1, and Spry2 in KPC KrasG12D/+ and KPC KrasG12D/fl PDAC tissue. Transcript levels were normalized to Gapdh (KPC KrasG12D/+, n = 5; KPC KrasG12D/fl, n = 6). Data represent the mean ± SEM. P = 0.2 (Etv4); **, P = 0.0087 (Etv5); P = 0.4 (Dusp4); **, P = 0.0087 (Dusp6); *, P = 0.0152 (Spry1); and *, P = 0.0411 (Spry2); ns, nonsignificant; one-way Mann–Whitney U test. Rel., relative.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Pancreatic cancer is characterized by the prevalence of oncogenic mutations in KRAS. Previous studies have reported that altered KRAS gene dosage drives progression and metastasis in pancreatic cancer. Whereas the role of oncogenic KRAS mutations is well characterized, the relevance of the partnering wild-type (WT) KRAS allele in pancreatic cancer is less well understood and controversial. Using in vivo mouse modeling of pancreatic cancer, we demonstrated that WT KRAS restrains the oncogenic impact of mutant KRAS and dramatically impacts both KRAS-mediated tumorigenesis and therapeutic response. Mechanistically, deletion of WT Kras increased oncogenic KRAS signaling through the downstream MAPK effector pathway, driving pancreatic intraepithelial neoplasia initiation. In addition, in the KPC mouse model, a more aggressive model of pancreatic cancer, lack of WT KRAS led to accelerated initiation but delayed tumor progression. These tumors had altered stroma and an enrichment of immunogenic gene signatures. Importantly, loss of WT Kras sensitized Kras mutant tumors to MEK1/2 inhibition though tumors eventually became resistant and then rapidly progressed. This study demonstrates the repressive role of WT KRAS during pancreatic tumorigenesis and highlights the critical impact of the presence of WT KRAS in both tumor progression and therapeutic response in pancreatic cancer.Significance:KRAS allelic status impacts pancreatic cancer progression and has the potential to guide effective treatment in a substantial subset of patients.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Pancreatic cancer is characterized by the prevalence of oncogenic mutations in KRAS. Previous studies have reported that altered KRAS gene dosage drives progression and metastasis in pancreatic cancer. Whereas the role of oncogenic KRAS mutations is well characterized, the relevance of the partnering wild-type (WT) KRAS allele in pancreatic cancer is less well understood and controversial. Using in vivo mouse modeling of pancreatic cancer, we demonstrated that WT KRAS restrains the oncogenic impact of mutant KRAS and dramatically impacts both KRAS-mediated tumorigenesis and therapeutic response. Mechanistically, deletion of WT Kras increased oncogenic KRAS signaling through the downstream MAPK effector pathway, driving pancreatic intraepithelial neoplasia initiation. In addition, in the KPC mouse model, a more aggressive model of pancreatic cancer, lack of WT KRAS led to accelerated initiation but delayed tumor progression. These tumors had altered stroma and an enrichment of immunogenic gene signatures. Importantly, loss of WT Kras sensitized Kras mutant tumors to MEK1/2 inhibition though tumors eventually became resistant and then rapidly progressed. This study demonstrates the repressive role of WT KRAS during pancreatic tumorigenesis and highlights the critical impact of the presence of WT KRAS in both tumor progression and therapeutic response in pancreatic cancer.Significance:KRAS allelic status impacts pancreatic cancer progression and has the potential to guide effective treatment in a substantial subset of patients.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Late-stage intervention with MEK1/2 inhibition improves survival of KPC KrasG12D/fl mice. A, Experimental schematic. KPC KrasG12D/+ and KPC KrasG12D/fl mice were palpated for tumor burden, with palpable tumor burden confirmed by ultrasound imaging, with mice treated continuously from the following day with either vehicle or AZD6244. Tumor growth was monitored by ultrasound imaging once weekly to clinical endpoint. B, Relative volume of pancreatic tumors arising in KPC KrasG12D/+ and KPC KrasG12D/fl mice treated with either vehicle control or AZD6244 from palpable tumor and aged to clinical endpoint. Tumor volume was measured once weekly by high-resolution ultrasound imaging. Each line represents an individual mouse of the indicated genotype and treatment. KPC KrasG12D/fl vehicle, n = 6; KPC KrasG12D/fl AZD6244, n = 7; KPC KrasG12D/+ vehicle, n = 6; KPC KrasG12D/+ AZD6244, n = 4. FC, fold change. C, Change of tumor volume (mm3) of KPC KrasG12D/+ and KPC KrasG12D/fl mice treated with either vehicle control or AZD6244 from palpable tumor between initial ultrasound measurement and a secondary ultrasound measurement (between 6 and 13 days later). Plot represents Log2(FC) of tumor volume between first and second measurements for the full treatment cohort when more than one imaging session was possible. KPC KrasG12D/fl vehicle, n = 5; KPC KrasG12D/fl AZD6244, n = 7; KPC KrasG12D/+ vehicle, n = 4; KPC KrasG12D/+ AZD6244, n = 4. D, Kaplan–Meier survival curves for KPC KrasG12D/+ and KPC KrasG12D/fl mice treated with vehicle or AZD6244, as indicated, from palpable tumor burden and aged to clinical endpoint. KPC KrasG12D/fl vehicle, n = 5; KPC KrasG12D/fl AZD6244, n = 8; KPC KrasG12D/+ vehicle, n = 6; KPC KrasG12D/+ AZD6244, n = 5. MS, median survival. E, Representative hematoxylin and eosin images of tumors from KPC KrasG12D/+ and KPC KrasG12D/fl mice treated with vehicle or AZD6244, as indicated, from palpable tumor burden and aged until clinical endpoint. Representative of five mice per group. Scale bar, 500 μm. F, Left, volcano plot for differentially expressed genes of KPC KrasG12D/+ tumors treated with vehicle or AZD6244 from palpable tumor burden to clinical endpoint. Right, volcano plot for differentially expressed genes of KPC KrasG12D/fl tumors treated with vehicle or AZD6244 from palpable tumor burden to clinical endpoint. Red, significantly altered genes. G, Schematic representing relative impact of WT Kras deletion upon tumur outgrowth and therapeutic responses from KPC KrasG12D/+ and KrasG12D/fl comparison.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Late-stage intervention with MEK1/2 inhibition improves survival of KPC KrasG12D/fl mice. A, Experimental schematic. KPC KrasG12D/+ and KPC KrasG12D/fl mice were palpated for tumor burden, with palpable tumor burden confirmed by ultrasound imaging, with mice treated continuously from the following day with either vehicle or AZD6244. Tumor growth was monitored by ultrasound imaging once weekly to clinical endpoint. B, Relative volume of pancreatic tumors arising in KPC KrasG12D/+ and KPC KrasG12D/fl mice treated with either vehicle control or AZD6244 from palpable tumor and aged to clinical endpoint. Tumor volume was measured once weekly by high-resolution ultrasound imaging. Each line represents an individual mouse of the indicated genotype and treatment. KPC KrasG12D/fl vehicle, n = 6; KPC KrasG12D/fl AZD6244, n = 7; KPC KrasG12D/+ vehicle, n = 6; KPC KrasG12D/+ AZD6244, n = 4. FC, fold change. C, Change of tumor volume (mm3) of KPC KrasG12D/+ and KPC KrasG12D/fl mice treated with either vehicle control or AZD6244 from palpable tumor between initial ultrasound measurement and a secondary ultrasound measurement (between 6 and 13 days later). Plot represents Log2(FC) of tumor volume between first and second measurements for the full treatment cohort when more than one imaging session was possible. KPC KrasG12D/fl vehicle, n = 5; KPC KrasG12D/fl AZD6244, n = 7; KPC KrasG12D/+ vehicle, n = 4; KPC KrasG12D/+ AZD6244, n = 4. D, Kaplan–Meier survival curves for KPC KrasG12D/+ and KPC KrasG12D/fl mice treated with vehicle or AZD6244, as indicated, from palpable tumor burden and aged to clinical endpoint. KPC KrasG12D/fl vehicle, n = 5; KPC KrasG12D/fl AZD6244, n = 8; KPC KrasG12D/+ vehicle, n = 6; KPC KrasG12D/+ AZD6244, n = 5. MS, median survival. E, Representative hematoxylin and eosin images of tumors from KPC KrasG12D/+ and KPC KrasG12D/fl mice treated with vehicle or AZD6244, as indicated, from palpable tumor burden and aged until clinical endpoint. Representative of five mice per group. Scale bar, 500 μm. F, Left, volcano plot for differentially expressed genes of KPC KrasG12D/+ tumors treated with vehicle or AZD6244 from palpable tumor burden to clinical endpoint. Right, volcano plot for differentially expressed genes of KPC KrasG12D/fl tumors treated with vehicle or AZD6244 from palpable tumor burden to clinical endpoint. Red, significantly altered genes. G, Schematic representing relative impact of WT Kras deletion upon tumur outgrowth and therapeutic responses from KPC KrasG12D/+ and KrasG12D/fl comparison.